Volume 10, Number 4—April 2004
Research
Antigenic and Genetic Variability of Human Metapneumoviruses
Bernadette G. van den Hoogen*, Sander Herfst*, Leo Sprong*, Patricia A. Cane†, Eduardo Forleo-Neto‡, Rik L. de Swart*, Albert D.M.E. Osterhaus*, and Ron A.M. Fouchier*
Table 2
Homologous and heterologous virus neutralizing antibody titers of serum samples obtained from ferrets infected with HMPV viruses belonging to different genetic sublineagesa,b
| Experiment | Virus used in virus neutralization | TCID50/well | Ferret 1 NL/1/00 [A1] | Ferret 2 NL/1/99 [B1] |
|---|---|---|---|---|
| 1 |
NL/1/00 |
12 |
1,024 |
32 |
| NL/1/99 |
9 |
16 |
512 |
|
| 2 |
NL/1/00 |
30 |
1,024 |
8 |
| NL/1/99 |
20 |
8 |
768 |
|
| 3 |
NL/1/00 |
40 |
768 |
24 |
| NL/1/99 |
25 |
16 |
768 |
|
| Ratio A–B |
48–128 |
|||
| Ratio B–A | 16–96 |
aVirus neutralizing antibody titers obtained in three independent experiments for serum samples collected 28 days postinfection from ferrets 1 and ferret 2 (infected with NL/1/00 and NL/1/99 respectively). TCID50, 50% tissue culture infectious dose; HMPV, human metapneumovirus.
bHomologous virus neutralization titers are bold. Values are average of duplicate measurements. Ratios are given as the homologous virus neutralization titers divided by the heterologous virus neutralization titers.
Page created: February 09, 2011
Page updated: February 09, 2011
Page reviewed: February 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential